Rebranding generics as branded medicines – CJEU issues new guidance

Written By

heidi hurdle Module
Heidi Hurdle

Professional Support Lawyer
UK

I am the Professional Support Lawyer to Bird & Bird's market-leading Intellectual Property group in London.

The CJEU has provided welcome new guidance on when parallel importers can rebrand generic medicines with the original trade mark of the reference medicinal product.

Its ruling in Impexeco NV v Novartis AG and PI Pharma NV v Novartis AG (Joined cases C 253/20 and C 254/20) is one of series of landmark judgments concerning parallel imports of pharmaceuticals released by the CJEU last month. (See our article here for details of these other judgments which put parallel imports and new anti-tampering devices under the spotlight.)

Full article available on BioTalk. Read more here

Latest insights

More Insights
featured image

Employment Litigation in Singapore: Employees Can Double-Strike with Employment Claims Tribunal Win Followed by High Court Claim

4 minutes Jul 11 2025

Read More
Curiosity line blue background

Sprinting to an IPO? ASIC trials a streamlined fast-track to the ASX

Jul 08 2025

Read More
featured image

EPO Upholds, UPC Revokes: A Tale of Diverging Views on PCSK9 Antibody Patent

2 minutes Jul 02 2025

Read More